Celldex Therapeutics, Inc.

  • Which Of These Smaller Companies Could Roche Buy?

    By Leo Sun - August 16, 2013 | Tickers: ALXN, CLDX, IMUC, IMMU, RHHBY

    Over this past year, the oncology treatment industry has been a hotbed of acquisition rumors, which caused analysts and investors to endlessly speculate on which companies will be swallowed up next by the larger fish in the sea. In a previous article, I visited the eye of the storm: Onyx Pharmaceuticals, which put itself on sale after a failed $8.7 billion buyout attempt from Amgen. Amgen is reportedly still more »

  • Which of These Biotech Stocks Will Appreciate Faster?

    By Brian Nichols - August 13, 2013 | Tickers: ACAD, CLDX

    ACADIA Pharmaceuticals (NASDAQ: ACAD) and Celldex Therapeutics (NASDAQ: CLDX) have become two of the best performing biotech stocks of the last 16 months. ACADIA has significantly outperformed Celldex during this period, but today, both stocks trade at prices pretty close to each other. Therefore, with prices just shy of $20, which stock will rise to $30 first, and become the best performer?

    A glance at both companies

    Both companies have more »

  • Inovio's Pipeline And Its Rise To Fame

    By Terry Chrisomalis - August 5, 2013 | Tickers: CLDX, INO, VICL

    There are many biotechs which are undervalued,because they are only in trials. But there are times when you can catch , if you look hard enough, at a gem biotech that is trading way below it's current value. This brings me to a biotech stock Inovio Pharmaceuticals Inc. (NYSEMKT: INO) This is one of a few biotech stocks that you can find that has a huge pipeline that trades more »

  • This Company Has Potential to Grow

    By usman iftikhar - August 5, 2013 | Tickers: CLDX, IMGN, SGEN

    Cancer is the target of a number of different biotech companies. Out of this lot, I consider Seattle Genetics (NASDAQ: SGEN) to be one of the star performers. Why is that? Because the company has one of the best antibody therapeutic study facilities and is one of the most successful in the industry. Its main focus is cancer, which is one of the leading causes of deaths in the U more »

  • A Company With a Lot of Positives

    By usman iftikhar - July 23, 2013 | Tickers: ALXN, CLDX, SGEN

    This year has brought great prospects for biotech companies. Despite the fact that the biotech industry is a speculative growth segment, investors poured their money into this industry. I think this change in the public’s investment decision is not due to some altered perception regarding stock purchases. They are still following the most basic guideline of investing: the greater the risk, the greater the return. The difference is that more »

  • The Upside in a Revolutionary Treatment For Brain Cancers

    By Kanak Kanti - July 22, 2013 | Tickers: CLDX, MRK, RHHBY

    Every year, 13,000 Americans die due to brain tumors, with glioblastoma multiforme (GBM), the most common form of brain cancer, being responsible for more than 50% of fatalities. GBM has an incidence rate of 12,000 new cases per year in the US alone. Conventional therapies like surgery, radiation and chemotherapy do not work well in the sensitive brain area and have too much collateral damage. Now, a novel more »

  • Rare Diseases and Rare Drugs Could Mean Great Gains For You

    By Madhukar Dubey - July 17, 2013 | Tickers: CLDX, INFI, KERX

    The U.S. is the largest market of biotechnology products in the world. There are more than 1,300 companies involved in the research and development of drugs, vaccines for cancer, infectious diseases, auto-immune conditions, HIV/AIDS, and other inflammatory diseases like asthma and arthritis. The total U.S. biotech market is expected to grow at an annual growth rate of 13.6% from 2009 to reach $22.8 billion more »

  • 4 Reasons This Biotech Went up by 400 Percent

    By Kanak Kanti - July 16, 2013 | Tickers: ALXN, CLDX, RHHBY

    Celldex (NASDAQ: CLDX), the first antibody-based immunotherapy company, has been a strong buy recommended by several analysts for some time now. Obviously analysts were bang on target as the stock has gone up more than 51% in a matter of five days and gained an astounding 400% in 52 weeks. The stock is currently trading at around $20 a pop, up from about $4 a year ago.What is moving more »

  • Buy These Biotech Companies for Long-Term Growth

    By Madhukar Dubey - July 15, 2013 | Tickers: ACAD, ALNY, CLDX

    According to IBISWorld, revenue of global biotechnology companies will surge to $262 billion this year, up by 12.7%, year-over-year. This growth is due to rising research and development of new drugs, along with well-established production, commercialization, and distribution processes.

    Here are three biotech companies that are developing new drugs, which have potential to provide upside to each company in the future. Will this potential translate into any interesting investment more »

  • Are These Top Biotech Performers Still Worth Buying?

    By Sherrie Stone - July 10, 2013 | Tickers: ACAD, CLDX, CLVS, CYTK, KERX

    Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry. Perhaps you already own one, or maybe a couple of these stocks? Maybe you are considering an investment? Well, let's take a look at the top 5 biotech performers, and determine whether larger gains will be realized.

    No. 5: Cancer Stock on the Move

    Celldex Therapeutics (NASDAQ: CLDX) has more »

  • Is This Rally Close to Over?

    By Sherrie Stone - July 9, 2013 | Tickers: CLDX, MRK, RHHBY

    I, for one, have been on the Celldex Therapeutics (NASDAQ: CLDX) bandwagon since December 2012. It was at this time that the outlook for Celldex changed from being a speculative biotechnology company to a real player in the cancer immunotherapy space with the clinical success of its breast cancer drug CDX-011.

    CDX-011 has created a lot of excitement, and rightfully so. It is successfully treating patients who have failed multiple more »

  • Celldex On The Rise

    By Terry Chrisomalis - July 3, 2013 | Tickers: ARIA, CLDX, SGEN

    There are many biotech stocks that target cancer, but what is good about Celldex Therapeutics (NASDAQ: CLDX) is that it is targeting many therapeutic areas as well as cancer. Celldex has gone up over 209% in one year. The reason for the rise is the results that the company has been putting out about its drug candidates, especially two of them. The company has diversified its pipeline into targeting cancers more »

  • 2 Biotech Stocks That Could Soon be Acquired

    By Sherrie Stone - June 28, 2013 | Tickers: ACAD, CLDX, JNJ

    While a company is in the clinical phase of development, there are roughly four catalysts that could move the stock higher.

    1. Expansion of intellectual property and patents (creates moderate movement)

    2. Partnership (creates moderate-large movement)

    3. Phase data (creates large movement)

    4. Acquisition (creates largest movement)

    The final catalyst is the one that I am reviewing today. I am looking at two companies that look to be attractive acquisition more »

  • A Trio of Cancer Immunotherapy Innovators

    By Seth Robey - June 14, 2013 | Tickers: BMY, CLDX, IMGN, RHHBY, SGEN

    The cancer world has been abuzz after an exciting ASCO conference.  Bristol-Myer's Squibb (NYSE: BMY) presented really promising updates for its PD-1 inhibitor nivolumab in late-stage melanoma, leading one Citigroup analyst to declare "the beginning of the end of cancer."  With Merck and Roche (NASDAQOTH: RHHBY) also boasting PD-1 inhibitors we can only hope someone has a magic bullet.  But is there space in this massive market for the more »

  • Good And Bad Breast Cancer Drugs

    By Sherrie Stone - June 14, 2013 | Tickers: CLDX, GALE, RHHBY

    With more than 230,000 women diagnosed with breast cancer in the U.S. annually – and Roche’s (NASDAQOTH: RHHBY) Herceptin producing annual sales of more than $5 billion – the potential for breast cancer drugs is enormous. While there are many companies developing drugs to treat the disease, there are two specifically with late-phase drugs that have been favorites in the market.

    A breakthrough drug

    Since the start of 2012 more »

  • A Promising Platform for Cancer Immunotherapy

    By Seth Robey - June 10, 2013 | Tickers: BMY, CLDX, DNDN, MRK

    A 2011 Nobel Prize in Physiology and Medicine is certainly impressive.  Using a novel cancer treatment on yourself is both impressive and courageous.  Dr. Ralph Steinman believed so enthusiastically in the cancer vaccines which he helped to develop that he used many of them to treat his own pancreatic cancer.  Surviving for five additional years, Steinman was able to use his position on the Scientific Advisory Board of Celldex (NASDAQ: CLDXmore »)

  • These 3 Biotech Stocks Look Interesting

    By Shas Dey - April 30, 2013 | Tickers: ARIA, ARRY, CLDX

    Three biotech companies are making themselves heard in the stock market. They are making a mark in the life sciences space with their unique mix of science and strategy.

    Ariad Pharmaceuticals (NASDAQ: ARIA) is on the focused approach trajectory, using its solid foundation in the sciences to fill the holes left open by big pharma. Celldex Therapeutics (NASDAQ: CLDX) is exercising first-mover advantage by developing a novel but potent approach more »

  • Celldex Is Still a Buy

    By Mohsin Saeed - March 26, 2013 | Tickers: AZN, CLDX, PFE

    There has been a significant rally in the share price of Celldex (NASDAQ: CLDX) recently. The stock is still showing positive momentum due to strong data on its drug trials. This positive data makes the company an attractive target for big pharmaceutical players like Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN). I believe that the positive momentum will continue and that Celldex is still a buy despite recent rallies. 

    Celldex more »

  • Noteworthy Upgrades on Friday: 2 to Buy & 2 to Sell

    By Brian Nichols - March 9, 2013 | Tickers: CLDX, CBI, HL, THC

    Celldex Therapeutics (NASDAQ: CLDX)

    On Friday, a slew of upgrades came rolling in on shares of Celldex Therapeutics after the biotechnology stock lost significant value following earnings, which were on Thursday. That same day (Thursday) I wrote an article telling investors to “buy,” and I guess I wasn’t alone, as Roth Capital, Cantor Fitzgerald, and Jefferies all issued positive notes and bullish price targets on the same day.

    The more »

  • Celldex May Soar in 2013

    By Michael Meyer - January 10, 2013 | Tickers: CLDX, SGEN

    With so many companies claiming to have found the miracle cure for all diseases, it can be a tough challenge to find the contenders instead of the pretenders.  But there is one company that appears to be getting closer to find the illusive treatment for breast cancer.  That company is Celldex Therapeutics (NASDAQ: CLDX).

    Celldex Therapeutics is a biopharmaceutical company focused on the development, manufacture, and commercialization of novel therapeutics more »

  • Page 1 of 2